Effect and Mechanism of ALPPS Operation on Liver Regeneration

Recruiting Observational Study
Hepato Cellular Carcinoma (HCC) Hepatobiliary Cancers Liver Cancer Liver Regeneration
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Study type
Observational
Participants needed
50 (estimated)
Sponsor
Haitao Zhao, MD · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hepatobiliary malignancies-principally hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)-are highly aggressive and often diagnosed at advanced stages. Curative-intent liver resection remains the standard for resectable disease; however, postoperative outcomes depend on an adequate functional future liver remnant (FLR). Associating Liver Partition and Portal Vein Ligation for Staged Hepat…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age: Patients aged 18 to 75 years 2. Diagnosis established: A diagnosis of hepatobiliary malignancy (including hepatocellular carcinoma and cholangiocarcinoma) was confirmed and evaluated as suitable for ALPPS surgery 3. Liver function status: preoperative Child-Pugh score A …
Contacts

Haitao Zhao

86-010-69156042

zhaoht@pumch.cn

CONTACT